
Before Web3 had a name, David Post was studying how institutions change. Now the Helix founder works in the stubborn space between a promising network and a business that actually runs.

His route from Michigan engineering classrooms to a $130 million clinical-stage company is a study in useful detours, patient capital and the discipline to stop doing everything at once.

After three decades moving between corporations, startups, and laboratories, the PhenoTap founder has narrowed his work to one stubborn bottleneck: the enzyme inside the sensor.